Telix Pharmaceuticals Ltd — Capital/Financing Update 2018

Jan 14, 2018

==> picture [143 x 79] intentionally omitted <==

Summary of Voluntary Escrow Arrangements

Melbourne (Australia) – 15[th] January 2018 . Telix Pharmaceuticals Limited (ASX.TLX) (“ Telix ”, the “ Company ”) advises that, further to the Appendix 3B lodged today regarding the application for quotation of previously unquoted securities, being certain fully paid ordinary shares (“ Shares ”) subject to ASX-imposed mandatory escrow arrangements, the following voluntary escrow arrangements remain in place in respect of the Shares.

• The total number of Shares subject to voluntary escrow is 51,635,586 Shares, representing 26.15% of the Company’s total issued Shares.

• Of these Shares:

• 12,692,308 Shares are subject to voluntary escrow until 15 February 2018 (i.e. 3 months from Telix’s listing on ASX on 15 November 2017);

• 32,918,663 Shares are subject to voluntary escrow until 15 November 2018 (i.e. 12 months from listing);

• 384,615 Shares are subject to voluntary escrow until 15 November 2019 (i.e. 24 months from listing); and

• 5,640,000 Shares are subject to voluntary escrowed for up to 48 months from listing (decreasing by equal increments of 1,410,000 Shares on 15 November of each year).

As at 15 January 2018, no Shares subject mandatory or voluntary escrow arrangements are tradeable.

Further information regarding the escrow arrangements applicable to the Company’s securities can be found at section 10.6 of Telix’s prospectus dated 16 October 2017, which is available at www.asx.com.au.

About Telix Pharmaceuticals Limited

Telix is an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR). The Company is developing an advanced portfolio of oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX).

For more information visit www.telixpharma.com.

Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited Email: chris@telixpharma.com

Investor and Media Relations Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au